European Market Report for Peripheral Intravenous Catheters 2017 - MedCore

European Market Report for Peripheral Intravenous Catheters 2017 - MedCore

  • November 2016 •
  • 165 pages •
  • Report ID: 4353011 •
  • Format: PDF
Description
The European PIVC market includes three segments: conventional PIVCs, safety PIVCs and midlines. The safety PIVC segment includes three sub-segments: active safety PIVCs, passive safety PIVCs and closed system PIVCs. The midline market comprises three sub-segments: conventional midlines, power-injectable midlines and all-in-one midlines. The PIVC markets in Europe were transformed in 2013 following the implementation of the directive by the Council of the European Union which aims to prevent needlestick injuries to healthcare workers. EU legislation as well as national legislation has put in place significant penalties for facilities that have a high incidence of needlestick injuries. To avoid the legal and health risks hospitals have been transitioning to the use of safety PIVCs. As a result, the conventional PIVC market will continue to decline over the forecast period. The value of the midline market is expected to increase strongly over the forecast period as adoption increases. The European peripheral intravenous catheters PIVC market includes three segments: conventional PIVCs, safety PIVCs and midlines. The safety PIVC segment includes three sub-segments: active safety PIVCs, passive safety PIVCs and closed system PIVCs. The midline market comprises three sub-segments: conventional midlines, power-injectable midlines and all-in-one midlines.
Abstract
Peripheral intravenous catheters (PIVCs), also known as short peripheral IV catheters, are the most commonly used type of vascular access catheters. Almost 90% of patients admitted to hospitals receive a vascular access device, the vast majority of which are PIVCs. These devices are intended for short-term use, usually no longer than three days, and are inserted into the median cubital vein or the forearm extending for only a few inches. Owing to their peripheral placement, these catheters cannot be used for infusing toxic, irritating or vesicant drugs, including most of those used for chemotherapy. The flow rates of PIVCs are lower than central line catheters, such as central venous catheters (CVCs), making them best suited for blood sampling and infusing fluids and medicine.
Scope:2013-2023
Companies
3DT Holdings LLC
3M
Access Scientific
Ambu Inc.
AngioDynamics
Artsana
B. Braun
Baxter International
Becton Dickinson
Bionic
C. R. Bard
Cardinal Health
CareFusion
Codan
Cook Medical
Covidien
Deltamed
Districlass Medical
Edwards Lifesciences
Endeavor Capital
Fresenius
Grupo Sendal
Interrad Medical
Investindustrial
Ivera Medical Corporation
Joline
Kimal
LPI
Medcomp
Medikit
Medtronic
Navilyst Medical
Nipro Medical
Nostix, LLC
Novico
Pentaferte
Perouse Medical
PFM Medical
PFM Medical
PositiveID Corp.
Rays
Romedex
Roundtable Healthcare
Safety Syringes Inc.
Semprus BioSciences
Smiths Medical
SonoSite, Inc.
Teleflex Medical
Terumo
Troge
Vascular Pathways, Inc.
VeriTeQ Acquisition Corp.
VigMed
V-Tech
Vygon